Background and objective: Transcriptional factor E2A is crucial for the normal development and differentiation of B and T lymphocytes. Dysregulation of E2A leads to leukemia and tumorigenesis of some solid tumors. The expression and clinical significance of E2A as well as its role in colorectal cancer (CRC) are still unknown. This study aims to assess E2A expression in CRC tissues, evaluate its prognosis value, and investigate its role in colon cancer cell growth.
Introduction
The mammalian E2A gene is located at chromosome 19 and is non-tissue-specifically and ubiquitously expressed in a wide range of cell types. Through alternative splicing, the E2A gene encodes two isoforms, E12 and E47 (collectively referred as E2A proteins), which both have the basic-Helix-Loop-Helix (bHLH) domain and could regulate gene transcription by binding to the E-box DNA sequences, CAGGTG. Though widely expressed, E2A is not essential in some organogeneses like skeletal or cardiac myogenesis, erythropoiesis, chondrogenesis, and neurogenesis [1] but plays an important role in the development and differentiation of B [2, 3] and T lymphocytes [4] . E2A deficient mice showed an arrest at the pro-B cell stage during B cell development [3] and transgenic expression of either E12 or E47 could partially rescue the B lymphopoiesis initiation; similarly, E2A deficiency led to a block at the earliest stage of T cell development [4] and disturbed thymocyte positive selection [5] . Moreover, E2A has been found to be involved in some cellular activities including cell differentiation [6] , proliferation [7] , apoptosis [8] , cell cycle [9] and epithelialmesenchymal transition (EMT) [10] .
Besides its crucial role in normal B and T cell development, E2A also participates in tumorigenesis. Studies had reported the well-established role of E2A in leukemogenesis: two fusion proteins, E2A-HLF [11] and E2A-PBX1 [12] , both containing the transactivation domain of E2A and the DNA-binding domain of HLF or PBX1, could lead to pro-B cell acute lymphoblastic leukemia (ALL) in adolescents and pre-B cell ALL in children respectively [13] . Moreover, E2A has been found to be involved in the oncogenesis of solid tumors, either as oncogene or as tumorsuppressor gene. Presence of E2A-PBX1 fusion protein in lung cancer was recently reported and it correlated with overall survival of patients with lung adenocarcinoma in situ [14] . Increased expression of E2A was detected in breast cancer [15, 16] and prostate cancer [17] , of which it was found to promote oncogenesis. However, mice with null mutation of E2A were susceptible to spontaneously developed thymic lymphomas [18] and loss of E2A in primary effusion lymphoma led to apoptosis resistance [19] , suggesting the alternative role of E2A as a tumorsuppressor gene. Furthermore, E2A expression has been proposed to be of diagnostic value in certain subtype of gastric MALT (mucosal-associated lymphoid tissue) lymphoma [20] . Taken together, E2A may act as a tumor-suppressor gene or as an oncogene in different cancers.
The expression of E2A in colorectal cancer (CRC) and its prognostic value have not been discussed before and it's still unknown whether E2A promotes or represses the development of CRC. In this study, to our knowledge, for the first time we investigated the clinical significance of E2A in CRC and found its usefulness as a prognostic marker; furthermore, we found E2A suppressed tumor growth by targeting miR-320a in colon cancer cells, demonstrating its tumor-suppressive role in CRC.
Methods

Patients and clinical specimens
A total of 98 colorectal cancer patients were included; the patients were treated with surgery between June 2007 and January 2008 at Shanghai Minimally Invasive Surgery Center. Patients were excluded if they: had received neoadjuvant chemoradiotherapy; had unresectable colorectal cancers; had tumors of other organs; were unlikely to be interviewed during the follow-up. Demographic and clinicopathological data were extracted by chart review. Patients were interviewed by telephone at three months, six months, and then annually after surgery. Tumor samples were cut immediately after surgical specimens' removal during the operations and then fixed with formalin and preserved at 4uC for two weeks before next treatment; normal tissues were defined as mucosa located at least 5cm away from the tumor margin and cut, fixed, preserved and treated as above. This study was conducted with the written informed consents of all enrolled patients before surgery and under the protocol approved by the Ethical Committee of Ruijin Hospital Shanghai Jiao Tong University School of Medicine.
Immunohistochemistry and scoring
Immunohistochemistry staining was performed as protocol previously described [21] . Briefly, after fixation with formalin, tissues were embedded with paraffin, cut, and mounted on slides. Then, slides were washed with xylene to deparaffinize, with graded ethanol to rehydrate, incubated with citrate buffer to retrieve antigen, and blocked with 3% H 2 O 2 to inactivate endogenous peroxidase. Slides were incubated with E2A primary antibody (Santa Cruz Biotechnology, Texas, USA; 1:200 dilution) at 4uC overnight, followed by incubation with horseradish peroxidase (HRP)-conjugated goat anti-rabbit secondary antibody (Santa Cruz) for 30 minutes at room temperature. Complex visualization was done with a 2-Solution DAB Kit (Invitrogen). Negative controls were obtained by replacing the E2A primary antibody with preimmune rabbit serum.
Slides were examined by two researchers (Huang and Quan) independently. Scoring criteria used were as previously described with minor modifications. Staining intensity was scored as 0 (no staining), 1 (weak staining), 2 (moderate staining), and 3 (strong staining); positive cells on each section were scored as 0 (less than 10%), 1 (10%-25%), 2 (26%-50%), and 3 (.50%). The final score was a product of scores of intensity and positive cell of each slide. Slides with score 0-3 were defined as low expression and 4-9 as high expression. 
Cell culture
Protein extraction and Western blot
Cells were harvested at a confluence of 80% with RIPA (Solarbio, Beijing, China) and the protein concentration was determined with BCA Protein Assay Kit (Thermo Scientific, USA) by measuring OD 562 using microplate reader (Epoch, BioTek, Winooski, USA). Western blot was performed according to previously reported protocol [22] and primary antibodies used were E2A (1:500, Santa Cruz Biotechnology, Texas, USA). GAPDH (Kangchen, Shanghai, China) was used as loading control.
RNA and microRNA isolation, qRT-PCR
Total cell RNAs were extracted using Trizol reagent (Invitrogen) and total cell microRNAs (miRNAs) were extracted with mirVana TM miRNA Isolation Kit (Applied Biosystems, Foster City, CA, USA). RNA reverse transcription was performed by using PrimeScript RT Master Mix Perfect Real Time (TaKaRa, Shiga, Japan). The mRNA level of E2A (forward: 59-CCACT TCACT GAGTC GCACAG-39; reverse: 59-GTCTC TCCCG AAGGA GGCATA-39) was evaluated by qRT-PCR, using SYBR Green PCR Master Mix (Applied Biosystems); the RNA level of GAPDH (forward: 59-GGAGC GAGAT CCCTC CAAAAT-39; reverse: 59-GGCTG TTGTC ATACT TCTCA TGG-39) was used for normalization. The expression of miR-320a was evaluated by qRT-PCR using Taqman microRNA RT Kit (Applied Biosystems, Foster City, CA, USA), TaqMan MicroRNA Assays (Applied Biosystems), and Taqman universal PCR master mix (Applied Biosystems, Foster City, CA, USA), in accordance with the manufacturers' instructions; the U6 miRNA level was used for normalization.
Lentiviral transfection for stable expression clones
E2A/shRNA-eGFP-lentivirus particles and E2A/sh-negative control (shNC)-eGFP-lentivirus particles, namely E2A/shRNA-LV and E2A/shNC-LV, were purchased from Novobio (Shanghai, China). shNC was synthesized with the same bases of shRNA but with scrambled sequence. Lentiviral transfection and cell screening were performed according to manufacturer's instruction to establish the E2A stably downregulated and the stably NC transefected SW480 clones, i.e. SW480/shE2A and SW480/shNC. Transfection efficiency was evaluated by visual examination of the percentage of eGFP-expressing cells under fluorescence microscope (Olympus, Tokyo, Japan), western blot, and qRT-PCR.
Transient transfection
Plasmids, pEZ-M29-E12 (plasmid encoding isoform E12), pEZ-M29-E47 (plasmid encoding isoform E47), pEZ-M29-NC (plasmid with negative control sequence) and vector controls were purchased from Genecopoeia (Rockville, MD, USA) and validated by sequencing; miRNA-320a mimics (double-strand RNA mole-cules mimicking miR-320a) and mimics NCs (negative control sequences based on C. elegans microRNAs have minimal sequence identity in human) were purchased from GenePharma (Shanghai, China). Cells of log phase were harvested and seeded in 6-well plates at a density of 4*10 5 cells/well, 24 hours before transfection. Lipofectamine 2000 (Invitrogen, USA) was used for transfection, in accordance with manufacturer's instruction. Efficiency of transient transfection was examined by western blot or qRT-PCR. Cells transfected with vectors were used as control.
Cell proliferation assay
Cell proliferation assay was performed with the Cell Counting Kit-8 (CCK8) (Dojindo, Kumamoto, Japan). Briefly, cells were digested with trypsin (Beyotime, Shanghai, China), washed with phosphate-buffered saline (PBS) twice, filtered with a strainer (BD Falcon), resuspended in RIPA 1640 medium, counted, and diluted to a final concentration of 5 cells/ml. Then cells were seeded in 96-well plates, 200 ml (1000 cells) per well, in sixplicate, and placed in the incubator for 6 days. Viable cells were quantified at each 24 h interval with CCK8, in accordance with manufacturer's protocol, and the absorbance at 450 nm was measured by using microplate reader (Epoch, BioTek).
Cell cycle analysis
Before analysis, cells ( 2610 6 ) were harvested 48 hours after transient transfection, as well as the corresponding controls. Then, cells were washed twice with ice-cold PBS, fixed with 75% ethanol and stored at 4uC overnight. Upon analyzing, cells were washed with PBS twice and treated with RNase at 37uC for an hour, followed by staining with Propidium Iodide for 30 minutes in dark. Cell cycle analysis was then performed with flow cytometry (FACSCalibur, Becton Dickinson, MD, USA).
Chromatin immunoprecipitation assay
EZ-ChIP TM Chromatin Immunoprecipitation Kit (Millipore, Billerica, MA, USA) was purchased to perform the ChIP assay, according to the manufacturer's protocol. Briefly, one 15 cm cell culture plate of SW480 cells (about 80% confluence) was fixed with 1% PFA (Sigma). Then cells were lysed, sonicated to shear DNA and immunoprecipitated with anti-E2A (Santa Cruz) and control antibody (IgG). After that, protein/DNA crosslink was reversed and DNA was purified for the following PCR, using Takara Ex Taq Hot Start Version (Takara).
Statistical analysis
All statistical analyses were conducted by using the SPSS 15.0 software. The correlation of clinical factors with E2A expression was examined by Pearson correlation analysis. The effect of E2A on survival was estimated using the Kaplan-Meier curve and logrank test. Univariate and multivariate Cox's proportional hazards model were used to evaluate the effects of E2A expression and clinicopathological parameters on 5-year OS and DFS, respectively. Student's t test was used to analyze differences between two groups and one-way ANOVA was employed in case of data consisted of more than two groups. A two-tailed value of P,0.05 was considered statistically significant.
Results
Expression of E2A correlated with CRC pathological stages
Firstly, we evaluated the expression of E2A protein in CRC tissues and normal mucosa by immunohistochemistry (Figure 1 ).
Colorectal tumor specimens obtained from 98 CRC patients and normal mucosa available from 43/98 patients were examined. The demographic and clinicopathological parameters of all included patients were shown in Table 1 . Of the 98 patients, high expression of E2A was detected in 35/43 normal mucosa and 39/98 tumor tissues (P,0.01). Staining of E2A in normal mucosa presented in nucleus and cytoplasm both, but in cancer tissues, E2A staining was predominantly nuclear (Figure 1 ). More importantly, expression of E2A decreased as CRCs advanced (Figure 1E-H) . We then made a correlation analysis to study the association between E2A expression and the clinicopathological factors. As shown in Table 2 , low expression of E2A was significantly associated with higher TNM stage (P,0.01) and larger tumor size (P = 0.035), but was not related to patients age (P = 0.761), gender (P = 0.655), tumor histology (P = 0.985), or tumor site (P = 0.120). Thus E2A was likely to be involved in the development and progression of CRC.
Low expression of E2A predicted poor prognosis of CRC patients
To investigate the prognostic value of E2A, we used KaplanMeier 5-year survival curve to show the differences in outcomes between low and high E2A expression CRC patients. As shown in Figure 2 , patients with high E2A expression had longer 5-year overall survival (OS) and disease free survival (DFS) than patients with low expression. The 5-year OS and DFS for high E2A expression patients were 84.6% and 82.1%, and for patients with low E2A expression were 47.5% and 42.4% (P = 0.000, for OS and DFS both). Next, we employed the Cox regression model to examine the prognostic value of E2A. In univariate analysis, TNM stage and E2A expression were found to be predictive for OS and DFS; while in multivariate analysis, both factors also predicted worse clinical outcomes (Table 3) . Hence E2A expression seemed to be a useful predictive factor for prognosis of CRC patients.
Inhibition of cell proliferation by E2A in CRC cells
Considering the clinical significance of E2A, we wanted to ask whether E2A played a role in the development of CRC. Six colon cancer cell lines, LOVO, HCT116, Caco-2, HT29, SW480, and SW1116 and normal human colon mucosal epithelium cell NCM460 were screened for E2A expression by using western blot ( Figure 3A) . Of the seven cell lines, NCM460 showed much higher E2A expression level than all other cancer cells. Taken together with its expression in CRC patients, E2A was significantly downregulated in CRC tissues and cells.
To directly investigate the function of E2A, we constructed E2A stably knocked-down clone, SW480/shE2A cells, and the negative control clone, SW480/shNC cells, with E2A/shRNA-LV and E2A/shNC-LV respectively. Knockdown efficiency was validated by western blot and qRT-PCR (Figure S1 A) . Then, we detected the cell proliferation changes of SW480/shE2A and SW480/ shNC cells with the MTT assay, using wild type SW480 cells (SW480/WT) as control. As shown in Figure 3B , SW480/shE2A showed higher proliferation rate than SW480/shNC and SW480/ WT cells, indicating a suppressive role of E2A in proliferation. To further demonstrate the anti-proliferation role of E2A, we performed co-transfection in stable SW480/shE2A cells with two plasmids, pEZ-M29-E12 (encoding isoform E12) and pEZ-M29-E47 (encoding isoform E47) to offset the downregulation effect by shE2A. Co-transfection rescued the E2A expression of SW480/ shE2A cells to normal level ( Figure S1 A) and also restored the proliferation rate ( Figure 3C ). Moreover, transfection of E12 or E47 into wild type SW480 cells could significantly inhibit cell proliferation and the inhibition effects caused by E12 and E47 did not show any differences (Figure S1 B) . To exclude the cell line dependent possibility, we constructed Caco-2/shE2A and Caco-2/ shNC clones to repeat the above experiments and results showed E2A had the same anti-proliferation role in Caco-2 cells (Figure 3D & E). Additionally, we manipulated the E2A expression in NCM460 cells. E2A silencing and restoration also affected NCM460 cell growth in a suppressive manner (Figure S1 C) . Conclusively, E2A might be a negative regulator of proliferation in colon cancer cells.
E2A regulated cell cycle progression of SW480 cells
Next we wanted to know the mechanisms through which E2A regulated SW480 cell proliferation. In previous publications, E2A was reported to be involved in cell cycle regulation [9, 23, 24] . Thus, we made cell cycle analysis by flow cytometry to detect potential changes after E2A downregulation and restoration. Consistently, the change of cell cycle explained alteration in cell proliferation: as shown in Figure 4A , cell cycle of SW480/shE2A cells differed from SW480/shNC and SW480/WT cells, with more cells progressed into S phase, indicating increased cell proliferation. When SW480/shE2A cells were co-transfected with either E12 or E47 plasmid, the cell cycle was normalized, which was in agreement with the restoration of cell proliferation ( Figure 4B ). Moreover, transfection of E12 or E47 into wild type SW480 resulted in a decrease of S phase cells ( Figure S1 D) . Similar regulation effects were also seen in NCM460 cells ( Figure   S1 E). Thus, E2A might regulate cell cycle to control cell proliferation.
E2A controlled cell cycle by targeting miR-320a
The findings above further led us to investigate how E2A regulated cell cycle change. In recent decades, microRNAs (miRNAs) have been found to be involved in the pathogenesis of human diseases including cancer [25] . Unexpectedly, we found one miRNA, miR-320a, which was a metastasis suppressor [26] , was regulated by E2A. In SW480/shE2A cells, the expression of miR-320a was downregulated ( Figure 5A ) and transfection of either E12 or E47 into this group of cells ( Figure 5B ) or into wild type SW480 cells ( Figure S1 F) could upregulate miR-320a. To investigate whether miR-320a was a target directly regulated by E2A, we performed the chromatin immunoprecipitation (ChIP) assay. Results showed that E2A could bind to the E-box (GCAGGTG, at -138bp, upstream of miR-320a stemloop) of miR-320a, suggesting E2A may regulate the expression of miR320a by targeting its promoter sequence directly ( Figure 5C ).
Then, we asked whether miR-320a was the target through which E2A regulated cell proliferation. By transfecting miR-320a mimics into SW480/shE2A cells, we found the cell cycle progression caused by E2A knockdown was arrested and cell proliferation rate was decreased ( Figure 5D & E) . Also, cotransfection of miR-320a mimics in Caco-2/shE2A cells inhibited cell proliferation rate ( Figure 5F ). Hence, E2A regulated cell proliferation by directly targeting miR-320a.
Discussion
Despite great efforts having been made to improve the prevention and treatment of CRC, its morbidity and mortality still remain high: both were estimated to be the third among all cancers in USA, 2013 [27] . The tumorigenesis of CRC is a multiple process mediated by accumulating alterations in cell proliferation ability and a wide range of genetic disorders [28] . Based on these, recent studies have focused on finding new biomarkers and aberrant genetic features in CRC [29] . Here we showed E2A was a novel prognostic marker for CRC and miR320a was a direct target through which E2A regulated colon cancer cell cycle to control cell proliferation. The role of E2A in normal B and T cell development and leukemogenesis has been well studied [13, 30, 31] and it was also demonstrated to be involved in breast cancer, prostate cancer, gastric MALT and thymic lymphoma [15, 17, 18, 20] . Specially, E2A expression is associated with tumor cell differentiation and patient outcome in breast cancer [15] and tumor stages in prostate cancer [17] . Hence, E2A is likely to be a factor linked with tumor development and have prognostic value. In supporting of this, we found that E2A expression was significantly decreased in CRC tissues compared with normal mucosa and immunohistochemistry showed a gradually decreased scoring of positive E2A staining as clinical stages advanced, indicating a negative association of E2A with CRC development and a probably tumor-suppressive effect of E2A. In Cox regression analysis, we found low expression of E2A predicted poor prognosis of OS and DFS in CRC patients independent of age, gender, tumor site, tumor histology, and tumor size. These results, which suggested a suppressive role of E2A in CRC, were in consistent with the findings in lymphoma [18, 32] and leukemia [4] , but contradicted with those found in breast and prostate cancer [15, 17] . Considering the multistep process of CRC carcinogenesis and different biological behaviors of tumors, the discrepancy could be understood at least partially.
Previous studies have shown the self-contradictive roles of E2A in proliferation: silencing of E2A in breast [15] and prostate cancer cells [17] inhibited cell growth, but in lymphoma, leukemia, hematopoietic stem cells, and CRC cancer cells, loss of E2A led to enhanced proliferation [7, 30, 32, 33] . Besides, enforced E47 overexpression inhibited cell growth of T cell ALL [34] . To clearly reveal the role of E2A in colon cancer cell proliferation, we constructed an E2A stably downregulated SW480 clone to investigate its effect. Consistent with prior results found in hematopoietic malignancy and CRC, we observed that downregulation of E2A significantly increased cell proliferation rate and co-transfection with either E12 or E47 plasmid could offset this effect, suggesting the direct role of E2A in regulating cell proliferation. Accordingly, cell cycle analysis showed a progression from G1/G0 phase to S phase in E2A downregulated cells. Although some studies showed cell cycle arrested at G1 phase in E2A deficient cancer cells [17, 23] , our results were supportive to the pro-proliferation effect and in agreement with the findings of most studies which showed accelerated cell cycle progression after E2A deficiency [24, [35] [36] [37] [38] [39] . Taken together, knockdown of E2A promoted cell cycle progression and this resulted in increased cell proliferation. These findings provide partial, if not complete, insights into the tumor suppressive role of E2A in CRC.
As a transcriptional factor, E2A exerts its functions by regulating gene expression and studies have reported its downstream targets including p21, Id1, c-Myc, etc [17, 24, 36] . In our study, we found miR-320a was a target regulated by E2A in modulating cell cycle and cell proliferation. Human miR-320a is localized at chromosome 8p21.3, a locus of liver metastatic susceptibility [40] , and it has been reported to be regulator of glycolysis [41] and dysregulated in cancer [42] . Studies have shown that miR-320a suppresses tumorigenesis and metastasis in CRC [26, 43, 44] . Unexpectedly, we identified the E-box of miR- 320a as a binding site of E2A with TESS (Transcription Element Search System) and we indeed demonstrated that E2A bound to miR-320a using ChIP assay. Expression of miR-320a was regulated by E2A directly and more importantly, upregulation of miR-320a could reverse the changes caused by E2A knockdown, which further suggested it as a downstream effector of E2A. Yet, it remains unclear whether the effect of E2A on miR-320a is a global effect. Taken together, we propose that miR-320a is one of the targets through which E2A regulates cell cycle progression and cell proliferation.
In summary, we present convincing evidence showing that E2A is a prognostic factor for CRC patients and plays a tumorsuppressive role in CRC cells. Through binding directly to miR320a, E2A regulates cancer cell cycle progression and controls cell growth. Yet, the role of E2A in solid tumors has not been fully understood and our findings only partially unveil the molecular targets and mechanisms of action of E2A. Hence, future studies are required to validate our findings and thoroughly elucidate the role of E2A in CRC. Author Contributions
Supporting Information
